Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2017

GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2017" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Eli Lilly and Company

AstraZeneca Plc

F. Hoffmann-La Roche Ltd

Sanofi

Merck & Co Inc

Bayer AG

Novartis AG

GlaxoSmithKline Plc

Agios Pharmaceuticals Inc

Celgene Corp

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials 20

Clinical Trials by Phase in E7 Countries 22

Clinical Trials in E7 Countries by Trial Status 23

Clinical Trials by Phase 25

In Progress Trials by Phase 26

Clinical Trials by Trial Status 27

Clinical Trials by End Point Status 29

Subjects Recruited Over a Period of Time 30

Clinical Trials by Sponsor Type 31

Prominent Sponsors 32

Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials 34

Prominent Drugs 36

Latest Clinical Trials News on Bile Duct Cancer (Cholangiocarcinoma) 37

Apr 21, 2017: Presentation of fimaCHEM Phase I data in bile duct cancer at The International Liver Congress 2017 37

Clinical Trial Profile Snapshots 38

Appendix 445

Abbreviations 445

Definitions 445

Research Methodology 446

Secondary Research 446

About GlobalData 447

Contact Us 447

Disclaimer 447

Source 448

List of Tables

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region, 2017* 7

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15

Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2017* 16

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19

Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2017* 21

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase, 2017* 26

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 27

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 32

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15

Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2017* 16

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19

Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2017* 21

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 26

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 27

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 30

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 31

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 32

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35

Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

GlobalData Methodology 447

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports